Coagulopathy and thrombocytopenia

12 min read Last updated April 9, 2026

Surgical approach (not a single operation, typical surgical responses to bleeding/coagulopathy)

  • Control bleeding source early: direct pressure, clamp/ligate, cautery, topical haemostats, packing
    • Damage control surgery if unstable: rapid haemorrhage control + temporary closure, definitive surgery later
    • Minimise ongoing blood loss: tourniquet (limb), pelvic binder, tamponade (e.g. uterine balloon), endoscopic haemostasis where appropriate
  • Correct reversible surgical contributors: hypothermia, acidosis, dilution, ongoing contamination/sepsis
    • Request early major haemorrhage protocol (MHP) and point-of-care coagulation testing (TEG/ROTEM) where available
  • Interventional radiology alternatives: embolisation (pelvis, postpartum haemorrhage, GI bleed), stenting

Anaesthetic management (context-dependent: bleeding/coagulopathy rather than a single procedure)

  • Type of anaesthesia: usually GA for active bleeding/major surgery, regional/neuraxial only if coagulation status acceptable and stable
    • Avoid neuraxial techniques in significant coagulopathy or severe thrombocytopenia, follow local/ASRA/ESAIC guidance and haematology advice
  • Airway: ETT often preferred (aspiration risk, need for controlled ventilation, prolonged surgery, massive transfusion), SGA only for low-risk, short cases with stable coagulation
  • Duration: variable (minutes for damage control to many hours for definitive surgery), plan for prolonged resuscitation and re-look surgery
  • Pain: depends on surgery, anticipate high pain for laparotomy/orthopaedics—use multimodal analgesia, consider regional blocks only if safe
    • If neuraxial contraindicated: consider IV opioids, ketamine, lidocaine infusion (selected), TAP/rectus sheath blocks if coagulation acceptable for fascial plane blocks
  • Monitoring/Access: 2 large-bore IVs, arterial line early, consider central access, active warming, urinary catheter, frequent labs/POC testing
    • Have rapid infuser/Level 1, blood warmer, pressure bags, calcium replacement plan
  • Resuscitation strategy: balanced blood components guided by MHP + TEG/ROTEM, permissive hypotension only in selected trauma without TBI
    • Early tranexamic acid (TXA) where indicated (e.g. trauma within 3 h, postpartum haemorrhage)

Definitions and classification

  • Coagulopathy: impaired haemostasis due to abnormalities of platelets, coagulation factors, fibrinogen, or fibrinolysis → bleeding and/or thrombosis
  • Thrombocytopenia: platelet count &lt,150 × 10^9/L (severity: mild 100–150, moderate 50–99, severe &lt,50, critical &lt,20)
  • Primary vs secondary haemostasis
    • Primary: platelet number/function + vWF → mucocutaneous bleeding (epistaxis, petechiae, menorrhagia)
    • Secondary: coagulation factors/fibrin → deep tissue bleeding (haemarthroses, muscle haematoma, delayed re-bleeding)

Causes (high-yield differentials)

  • Dilutional/consumptive (perioperative/critical care): massive haemorrhage, trauma-induced coagulopathy, DIC, liver failure, sepsis, hypothermia, acidosis, hypocalcaemia
  • Drug-related
    • Anticoagulants: warfarin, DOACs (apixaban/rivaroxaban/edoxaban, dabigatran), heparins
    • Antiplatelets: aspirin, clopidogrel/prasugrel/ticagrelor, GP IIb/IIIa inhibitors
    • Other: valproate (platelet dysfunction), SSRIs (platelet serotonin), antibiotics (rare), chemotherapy
  • Thrombocytopenia mechanisms
    • Reduced production: marrow failure, chemotherapy, B12/folate deficiency, alcohol, sepsis
    • Increased destruction/consumption: ITP, TTP/HUS, DIC, sepsis, HIT, immune drug-induced
    • Sequestration: hypersplenism (portal HTN, liver disease)
    • Dilution: massive transfusion/fluids
    • Pseudothrombocytopenia: EDTA-related platelet clumping (repeat in citrate tube, blood film)
  • Inherited bleeding disorders (important perioperative)
    • von Willebrand disease (most common): platelet adhesion defect + low factor VIII, mucosal bleeding
    • Haemophilia A (VIII) / B (IX): deep bleeding, prolonged APTT

Assessment: history and examination

  • Bleeding history: easy bruising, epistaxis, gum bleeding, menorrhagia, postpartum bleeding, surgical/dental bleeding, delayed re-bleeding
  • Drug history: anticoagulants/antiplatelets, herbal supplements (e.g. ginkgo), recent antibiotics, chemotherapy
  • Systemic disease: liver disease, renal failure (uraemic platelet dysfunction), sepsis, malignancy, autoimmune disease, pregnancy (HELLP)
  • Examination: petechiae/purpura (platelet), ecchymoses, mucosal bleeding, haemarthrosis (factor deficiency), jaundice/hepatosplenomegaly

Investigations: what they mean and limitations

  • FBC: platelet count, Hb trend, blood film (schistocytes in TTP/DIC, clumping in pseudo-thrombocytopenia)
  • PT/INR: extrinsic/common pathway (VII, X, V, II, fibrinogen), sensitive to warfarin, liver disease, vitamin K deficiency
  • APTT: intrinsic/common (XII, XI, IX, VIII, X, V, II, fibrinogen), prolonged in heparin, haemophilia, lupus anticoagulant (thrombosis risk)
  • Fibrinogen (Clauss): low in DIC/massive haemorrhage, key target in obstetric haemorrhage
  • D-dimer/FDP: elevated in DIC/lysis, non-specific
  • TEG/ROTEM: whole-blood viscoelastic testing—faster functional assessment, helps target fibrinogen vs platelets vs factors vs fibrinolysis
    • Limitations: may miss specific platelet drug effects, interpretation requires training, results depend on temperature/haematocrit
  • Renal/liver function, calcium, ABG (pH/lactate), temperature: correctable drivers of coagulopathy

Key perioperative targets (pragmatic)

  • Temperature: aim normothermia (hypothermia impairs platelet function and enzyme kinetics)
  • pH: treat acidosis (reduces coagulation factor activity, worsens shock)
  • Ionised calcium: maintain (citrate in transfused blood chelates Ca2+ → hypotension/coagulopathy)
  • Fibrinogen: early replacement if low/bleeding (often first factor to fall in major haemorrhage)
  • Platelets: maintain adequate count for procedure/bleeding risk (see thresholds below)

Platelet thresholds (exam-friendly, typical practice, confirm local policy)

  • Prophylactic platelet transfusion (non-bleeding): often &lt,10 × 10^9/L (or &lt,20 with additional risk factors), specialist-led
  • Most surgery / active bleeding: aim ≥50 × 10^9/L
  • Major surgery with high bleeding risk (e.g. neurosurgery, posterior eye surgery): aim ≥100 × 10^9/L
  • Neuraxial anaesthesia: depends on context and trend, commonly ≥75–80 × 10^9/L for epidural/spinal if stable and no other coagulopathy, obstetrics may accept lower in selected cases with senior decision-making
    • Consider platelet trend, cause (ITP vs pre-eclampsia/HELLP), other coag tests, clinical bleeding, and availability of urgent imaging/neurosurgery

Management of coagulopathy in major haemorrhage (principles)

  • Activate MHP early, communicate with lab and blood bank, assign roles, use checklists
  • Balanced component therapy while awaiting results (local packs often approximate RBC:FFP:platelets ~1:1:1) then switch to goal-directed therapy (TEG/ROTEM/labs)
  • Fibrinogen replacement: cryoprecipitate or fibrinogen concentrate (if available) when fibrinogen low or ROTEM suggests low clot amplitude due to fibrinogen deficit
  • FFP: replaces multiple factors, used for bleeding with prolonged PT/APTT or as part of MHP, avoid using FFP solely to &#039,correct INR&#039, in non-bleeding unless procedure requires
  • Platelets: treat thrombocytopenia or platelet dysfunction with bleeding, consider additional platelets if on antiplatelet agents and life-threatening bleeding (specialist advice)
  • TXA: early in trauma (within 3 hours) and postpartum haemorrhage, consider in other major bleeding per local policy
  • Avoid iatrogenesis: excessive crystalloids (dilution), hypothermia, high chloride acidosis, ensure warming and calcium replacement

Reversal of anticoagulants (high-yield perioperative)

  • Warfarin: vitamin K (IV for urgent reversal) + 4-factor PCC for major bleeding/urgent surgery, FFP if PCC unavailable
  • Unfractionated heparin: protamine (titrate to dose/time, risk hypotension/anaphylactoid reactions)
  • LMWH: protamine partially reverses (best within hours of dose), consider time since last dose and renal function
  • Dabigatran: idarucizumab for life-threatening bleeding/urgent surgery, dialysis can remove dabigatran if needed
  • Factor Xa inhibitors (apixaban/rivaroxaban/edoxaban): andexanet alfa where available for life-threatening bleeding, otherwise 4-factor PCC often used off-label per local guidance
  • Antiplatelets: no specific reversal for aspirin/P2Y12, options in major bleeding include platelet transfusion (timing matters), TXA, DDAVP in selected cases, seek haematology/cardiology input if recent stent

Specific perioperative thrombocytopenia syndromes (recognise and act)

  • HIT (heparin-induced thrombocytopenia): platelet fall typically 5–14 days after heparin (or sooner with prior exposure) + thrombosis risk, stop all heparin and use non-heparin anticoagulant (specialist-led)
    • Do NOT give platelets routinely unless life-threatening bleeding or urgent surgery (may worsen thrombosis risk)
  • TTP/HUS: microangiopathic haemolysis + thrombocytopenia ± neuro/renal, urgent plasma exchange, avoid platelet transfusion unless life-threatening bleeding
  • ITP: isolated thrombocytopenia, treat with steroids/IVIG for urgent procedures, platelet transfusion often short-lived but can be used with IVIG/steroids if emergency surgery/bleeding
  • DIC: consumption of platelets and factors (low fibrinogen, prolonged PT/APTT, high D-dimer), treat cause + supportive blood components guided by bleeding and labs/TEG
  • Liver disease: reduced synthesis of pro/anti-coagulants, INR may not reflect bleeding risk, consider TEG/ROTEM, correct fibrinogen/platelets if bleeding or before high-risk procedures
  • Uraemia: platelet dysfunction, consider dialysis, DDAVP, TXA (selected), and optimise anaemia

Neuraxial and regional anaesthesia considerations

  • Assess: platelet count and trend, coagulation tests, drug timing (DOAC/LMWH), liver/renal disease, clinical bleeding, and procedural risk (epidural &gt, spinal)
  • If neuraxial performed: minimise traumatic attempts, senior operator, document decision-making, plan postoperative neuro checks and escalation for back pain/weakness/bladder dysfunction
  • Peripheral nerve blocks: compressible superficial blocks generally lower risk than neuraxial, deep plexus blocks (lumbar plexus, paravertebral) carry higher bleeding risk—treat similarly to neuraxial in anticoagulated patients

Practical approach to the bleeding perioperative patient (structured)

  • A–E resuscitation + haemorrhage control, call for help early (senior anaesthetist, surgeon, haematology, transfusion lab)
  • Send bloods early and repeatedly: FBC, PT/INR, APTT, fibrinogen, group &amp, screen/crossmatch, ABG with Ca2+, lactate, use TEG/ROTEM if available
  • Start MHP if criteria met, use rapid infuser/warming, give TXA when indicated, replace calcium
  • Targeted component therapy: fibrinogen first if low, then platelets and plasma guided by results, consider PCC for warfarin/DOAC-related bleeding per policy
  • Reassess continuously: surgical field bleeding, haemodynamics, temperature, acid-base, ionised calcium, coagulation results, avoid over-transfusion and monitor for complications

Test yourself…

You are called to theatre for ongoing surgical bleeding. Outline your immediate anaesthetic priorities and how you would manage suspected coagulopathy.

Aim: stabilise physiology, stop bleeding, correct coagulopathy with a structured approach.

  • Call for help and activate major haemorrhage protocol early, allocate roles, inform blood bank and haematology
  • A–E: secure airway (often ETT), 100% O2, controlled ventilation, treat shock with blood products rather than large volumes of crystalloid
  • Access/monitoring: 2 large-bore IVs, arterial line, consider central line, rapid infuser and blood warmer, active warming
  • Investigations: FBC, PT/INR, APTT, fibrinogen, group &amp, crossmatch, ABG including ionised Ca2+, lactate, TEG/ROTEM if available
  • Treat reversible drivers: hypothermia, acidosis, hypocalcaemia, maintain perfusion and oxygen delivery
  • Blood components: balanced transfusion initially then goal-directed, early fibrinogen replacement if low, platelets if low/bleeding, plasma for factor deficiency
  • Adjuncts: TXA when indicated, consider anticoagulant reversal (vit K/PCC, protamine, specific DOAC antidotes) based on history and urgency
A patient has platelets 45 × 10^9/L and needs emergency laparotomy for perforation. What is your plan regarding platelets and anaesthetic technique?

Emergency high-risk surgery + likely sepsis/consumption → prioritise GA and haemostatic optimisation.

  • Choose GA with ETT (aspiration risk, sepsis, potential haemodynamic instability), avoid neuraxial
  • Aim platelet count ≥50 × 10^9/L for major surgery, transfuse platelets if bleeding or prior to incision depending on urgency and cause
  • Send coagulation labs and fibrinogen, consider TEG/ROTEM, treat sepsis physiology (warming, calcium, acid-base)
  • If thrombocytopenia is due to DIC/sepsis, expect ongoing consumption: repeat counts and give further platelets guided by bleeding and results
Discuss the causes of thrombocytopenia in the perioperative period and how you would distinguish them.

Use mechanism-based categories and time course, confirm with repeat testing and film.

  • Reduced production: marrow suppression/chemo, B12/folate deficiency, alcohol—typically chronic, other cell lines may be low
  • Increased destruction: ITP (isolated), drug-induced immune, HIT (timing 5–14 days + thrombosis), TTP (neuro/renal + schistocytes)
  • Consumption: DIC (prolonged PT/APTT, low fibrinogen, high D-dimer), sepsis/trauma
  • Sequestration: hypersplenism (liver disease, portal HTN) with splenomegaly
  • Dilutional: massive transfusion/large fluid volumes
  • Pseudothrombocytopenia: EDTA clumping—repeat in citrate tube and check film
How do PT/INR and APTT relate to the coagulation cascade, and what are their limitations in predicting bleeding?

They measure plasma-based clot initiation, not whole-blood haemostasis.

  • PT/INR: extrinsic/common pathway, sensitive to factor VII and warfarin, prolonged in liver disease/vit K deficiency
  • APTT: intrinsic/common, prolonged in heparin, haemophilia, inhibitors (e.g. lupus anticoagulant)
  • Limitations: do not assess platelet function, vWF, fibrinolysis, clot strength, poor correlation with bleeding in liver disease, affected by sampling/temperature
  • Viscoelastic tests (TEG/ROTEM) provide functional whole-blood information and can guide targeted therapy
A trauma patient is cold, acidotic and bleeding. Explain how hypothermia, acidosis and hypocalcaemia worsen coagulopathy and what you will do.

This is the lethal triad/diamond concept: physiology drives coagulopathy.

  • Hypothermia: impairs platelet function and slows enzymatic reactions of coagulation factors → weak clot
  • Acidosis: reduces activity of coagulation enzymes and worsens haemodynamics
  • Hypocalcaemia: citrate from transfused blood chelates Ca2+ (required for multiple coagulation steps) → hypotension and coagulopathy
  • Management: active warming, warmed fluids/blood, minimise exposure, restore perfusion and ventilation, monitor and replace ionised calcium, use MHP and targeted components
Outline a practical approach to managing warfarin-associated major bleeding requiring emergency surgery.

Reverse quickly and definitively while resuscitating and controlling bleeding.

  • Resuscitate and control bleeding, activate MHP if needed, send coagulation tests
  • Give IV vitamin K for sustained reversal
  • Give 4-factor PCC for rapid INR correction in major bleeding/urgent surgery (dose per INR/weight/local policy)
  • If PCC unavailable: consider FFP (slower, larger volumes) and manage volume overload risk
  • Recheck INR/TEG and clinical bleeding, avoid overcorrection and consider thrombosis risk post-op
A patient on apixaban presents with intracranial haemorrhage. What reversal options exist and what factors influence your choice?

Life-threatening bleeding: consider specific antidote if available, otherwise PCC-based strategies per policy.

  • Assess last dose timing, renal function, interacting drugs, send anti-Xa level if available (do not delay treatment in critical bleed)
  • Andexanet alfa may be used where available for life-threatening factor Xa inhibitor bleeding (institutional criteria apply)
  • If andexanet not available/appropriate: 4-factor PCC often used off-label per local guidance
  • Supportive care: neurosurgical involvement, BP control, avoid hypothermia/acidosis, consider TXA per local protocol
Explain the role of fibrinogen in major haemorrhage and how you replace it.

Fibrinogen is crucial for clot formation and platelet aggregation, it can fall early.

  • Low fibrinogen is associated with worse bleeding, particularly important in obstetric haemorrhage and trauma
  • Measure Clauss fibrinogen and/or use ROTEM fibrin-based assays to identify deficiency
  • Replace with cryoprecipitate or fibrinogen concentrate (if available), recheck levels and clinical response
You are asked to site an epidural for laparotomy. Platelets are 78 × 10^9/L, stable over 48 hours, normal PT/APTT, no bleeding history. How would you approach this decision?

Neuraxial decision is individualised: balance benefits vs risk of epidural haematoma.

  • Confirm cause and trend, exclude additional coagulopathy (liver disease, DIC), and review drugs (LMWH/DOAC timing)
  • Discuss with surgical team and patient, consider alternatives (IV PCA, fascial plane blocks) if risk unacceptable
  • If proceeding: senior operator, minimise attempts/trauma, document rationale, plan post-op neuro observations and clear escalation pathway
  • Consider that epidural catheter removal is also a risk point—plan timing with anticoagulant dosing and platelet monitoring
Describe heparin-induced thrombocytopenia (HIT) and its perioperative implications.

HIT is a prothrombotic immune complication of heparin exposure.

  • Features: platelet fall &gt,50% typically 5–14 days after heparin (or rapid with recent exposure), thrombosis, skin necrosis, bleeding is less prominent
  • Immediate management: stop all heparin (including flushes), use alternative anticoagulation (specialist-led), send HIT testing
  • Avoid routine platelet transfusion unless life-threatening bleeding/urgent surgery
  • Perioperative planning: anticoagulation strategy for CPB/vascular procedures requires haematology/cardiac anaesthesia input
A patient with liver disease has INR 2.2 but is not bleeding. Does this predict bleeding risk and should you correct it before a procedure?

INR in liver disease is an imperfect marker, haemostasis may be &#039,rebalanced&#039,.

  • INR reflects reduced procoagulant factors but does not account for reduced anticoagulant factors (protein C/S, antithrombin) or platelet/vWF changes
  • Bleeding risk depends on procedure, platelet count/function, fibrinogen, portal HTN, and clinical bleeding history
  • Avoid reflex FFP to correct INR in non-bleeding patients, consider TEG/ROTEM and correct specific deficits (e.g. fibrinogen/platelets) for high-risk procedures

0 comments